Top news from Heart in Diabetes: Updates in AI, COVID-19 and SGLT2 inhibition

Healio and Cardiology Today have curated a list of the top-read news from the virtual Heart in Diabetes CME Conference.

Readers were most interested in the CV impact of COVID-19, benefits of AI in diabetes, findings from DARE-19 and more.

COVID-19 pandemic may impact CV health despite infection status in patients

COVID-19 not only affects the CV health of infected patients, but it also affects the CV care of patients even in the absence of infection, according to two presentations. Read more

Braunwald: SGLT2 inhibitors have influenced CV care regardless of diabetes status

Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes, Cardiology Today Editorial Board Member Eugene Braunwald, MD, said in a presentation. Read more

AI can benefit care of patients with CVD, diabetes

Artificial intelligence has the ability to affect CV and diabetes care for both patients and clinicians, a presenter said. Read more

Proactive measures can reduce COVID-19 severity risk in obesity

Obesity and elevated BMI are “the common soil” that grow adverse outcomes related to COVID-19, and clinicians must work with patients to appropriately control risk factors for severe disease, according to a speaker. Read more

Triple combination therapy may be optimal for CV protection in type 2 diabetes

Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for CV and renal protection in type 2 diabetes, according to a speaker. Read more

CGM provides cost savings, health benefits for people with diabetes

Continuous glucose monitoring not only leads to better glycemic management for people with diabetes, but could also lead to cost savings, according to a speaker. Read more

DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19

SGLT2 inhibitors could potentially target key mechanisms activated in COVID-19, increasing lipolysis, reducing glycolysis, inflammation and oxidative stress, and improving endothelial function to reduce organ damage, according to a speaker. Read more

A ‘chicken or egg’ problem: Targeting timing of CV complications in type 2 diabetes

Lifestyle or medical therapy in prediabetes to reduce later CV events in type 2 diabetes may seem wise, yet little evidence demonstrates such strategies make a difference, according to a speaker. Read more

Hyperglycemia in type 1 diabetes may drive cardiac autoimmunity

Hyperglycemia is associated with the presence of multiple cardiac antibody types among people with type 1 diabetes, suggesting a novel mechanism for increased CV risk specific to the disease, according to a speaker. Read more

SGLT2s, GLP-1s benefit both sexes despite greater CV risks among women with diabetes

The increased risks for CVD conferred by diabetes are greater for women than for men, but the newer diabetes drug classes reduce those risks similarly for both sexes, according to a speaker. Read more